{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-062930","form_type":"8-K","ticker":"RNAZ","cik":"0001829635","company_name":"Transcode Therapeutics, Inc.","filed_at":"2023-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.958469+00:00","generated_at":"2026-06-14T18:28:29.021680+00:00","sec_items":["3.03","5.03","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"TransCode Therapeutics effects 1-for-20 reverse stock split to meet Nasdaq bid price rule","bullets":["1-for-20 reverse split effective 4:05 pm ET May 22, 2023; trading on split-adjusted basis begins May 23.","Pre-split outstanding shares ~16,998,534 reduced to ~849,926 post-split shares.","Reverse split intended to satisfy Nasdaq minimum $1.00 bid price continued listing requirement.","No fractional shares issued; cash paid for fractional interests based on May 22 closing price.","Trading symbol RNAZ unchanged; new CUSIP 89357L 204; Vstock Transfer LLC acting as exchange agent."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-062930","json":"https://secwatch.observer/filing/0001104659-23-062930.json","markdown":"https://secwatch.observer/filing/0001104659-23-062930.md","text":"https://secwatch.observer/filing/0001104659-23-062930.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829635/000110465923062930/0001104659-23-062930-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829635/000110465923062930/tm2316322d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T18:28:29.021680+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c785b52688c655849b423af9466a2e60c7e73cc2","claim":"Transcode Therapeutics, Inc.: Filed Certificate of Amendment to effect a 1-for-20 reverse stock split of common stock (effective 2023-05-22).","evidence_excerpt":"On May 19, 2023, TransCode Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment (the “Certificate of Amendment”) to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split (the “Reverse Split”) of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”), as of 4:05 p.m. Eastern Time on May 22, 2023 (the “Effective Time”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1829635/000110465923062930/0001104659-23-062930-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-05-22"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}